1. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Issue 3 (March 2022) Authors: Karakas, Mahir; Akin, Ibrahim; Burdelski, Christoph; Clemmensen, Peter; Grahn, Hanno; Jarczak, Dominik; Keßler, Mirjam; Kirchhof, Paulus; Landmesser, Ulf; Lezius, Susanne; Lindner, Diana; Mebazaa, Alexandre; Nierhaus, Axel; Ocak, Anil; Rottbauer, Wolfgang; Sinning, Christoph; Skurk, Carsten; Söff... Journal: Lancet Issue: Volume 10:Issue 3(2022) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗